Results 151 to 160 of about 1,093,427 (365)

Risk of ischemic heart disease in women after radiotherapy for breast cancer.

New England Journal of Medicine, 2013
S. Darby, M. Ewertz, P. McGale, A. Bennet, U. Blom-Goldman, D. Brønnum, C. Correa, D. Cutter, Giovanna Gagliardi, B. Gigante, M. Jensen, A. Nisbet, R. Peto, K. Rahimi, Carolyn Taylor, P. Hall   +15 more
semanticscholar   +1 more source

Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial

, 2010
Background: Postoperative radiotherapy decreases the risk for local and improves overall survival in women with breast cancer. We have limited information on radiotherapy-induced symptoms 10-17 years after therapy.
Sundberg, Agnetha,, Holmberg, Erik, Anderson, Harald, Karl-Axel Johansson, Malmström, Per,, Sundberg, Agnetha, David Alsadius, Alsadius, D, Alsadius, David, Johansson, Karl-Axel, Gustafsson, M, Per Malmström, Karlsson, Per, Per Karlsson, Sundberg, A, Holmberg, Erik,, Malmström, P, Wilderang, Ulrica, Dan Lundstedt, Ulrica Wilderäng, Anderson, H, Gunnar Steineck, Gustafsson, Magnus,, Erik Holmberg, Harald Anderson, Holmberg, E, Johansson, K-A, Lundstedt, D, Johansson, Karl-Axel,, Lundstedt, Dan, Lundstedt, Dan,, Karlsson, Per,, Steineck, Gunnar,, Wilderäng, U, Magnus Gustafsson, Agnetha Sundberg, Wilderäng, Ulrica,, Gustafsson, Magnus, Malmström, Per, Steineck, Gunnar, Alsadius, David,, Lund University., Steineck, G,   +42 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

New England Journal of Medicine, 2006
J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin, R. Cohen, Christopher U. Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M. Kies, J. Baselga, H. Youssoufian, N. Amellal, E. Rowinsky, E. Rowinsky, K. Ang   +17 more
semanticscholar   +1 more source

Immune Checkpoint-Related Gene Polymorphisms and High Serum Concentration of PD-L1 and CTLA4 Contribute to the Resistance to Platinum-Based Chemotherapy in Cervical Cancer

International Journal of Women's Health
Hongqin Yuan,* Xinfeng Wang,* Kaidong Liu, Jia Zhang, Pei Wang Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to ...
Yuan H, Wang X, Liu K, Zhang J, Wang P
doaj  

Experimental studies of the endolymphatic radiotherapy

, 1974
By injecting 131I-Lipiodol into lymphatics of the dorsum of dog feet, the distribution of 13JI in the lymph nodes and other principal organs as well as its histological effect were studied periodically after the injection for the period of two months ...
Irino, Shozo, Uno, Junichiro, Tanji, Tameyo, Oka, Akira   +3 more
core   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

New England Journal of Medicine, 2017
F. Hamdy, J. Donovan, J. Lane, M. Mason, C. Metcalfe, P. Holding, M. Davis, Timothy J. Peters, E. Turner, Richard M. Martin, J. Oxley, M. Robinson, J. Staffurth, E. Walsh, P. Bollina, J. Catto, A. Doble, A. Doherty, D. Gillatt, R. Kockelbergh, H. Kynaston, A. Paul, P. Powell, S. Prescott, Derek J. Rosario, E. Rowe, David E. Neal, David E. Neal   +27 more
semanticscholar   +1 more source

Good tolerance and long-term complete remission after definitive intensity-modulated radiotherapy for locally advanced head and neck cancer in a patient with human immunodeficiency virus infection: A case report and literature review

, 2017
Background. The main concerns with radiation therapy for head and neck cancer in human immunodeficiency virus (HIV)-infected patients include limited tumor response and profound mucosal or skin toxicities under severe immunocompromised status.
Chen, Wan-Yu;Kuo, Sung-Hsin;Shen, Chia-Wei;Huang, Bing-Shen;Lan, Keng-Hsueh;Liang, Hsiang-Kuang;Wang, Chun-Wei, 陳婉瑜;郭頌鑫;藍耿學;梁祥光;王駿瑋   +1 more
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source